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Abstract 34 
The calcium sensing receptor (CaSR) was cloned over 20 years ago and 35 
functionally demonstrated to regulate circulating levels of parathyroid hormone 36 
by maintaining physiological serum ionized calcium (Ca2+) concentration. The 37 
receptor is highly expressed in the kidney; however, intra-renal and intra-38 
species distribution remains controversial. Recently, additional functions of the 39 
CaSR receptor in the kidney have emerged, including parathyroid hormone 40 
independent effects. It is therefore critical to establish unequivocally the 41 
localization of the CaSR in the kidney in order to relate this to its proposed 42 
physiological roles. In this study we determined CaSR expression in mouse, rat 43 
and human kidney using in situ hybridisation, immunohistochemistry (using 44 
eight different commercially available and custom-made antibodies) and 45 
proximity ligation assays. Both in situ hybridisation and immunohistochemistry 46 
showed CaSR expression in the thick ascending limb, distal tubule and 47 
collecting duct of all species, with the thick ascending limb showing the highest 48 
levels. Within the collecting ducts there was significant heterogeneity of 49 
expression between cell types. In the proximal tubule, lower levels of 50 
immunoreactivity were detected by immunohistochemistry and proximity ligation 51 
assays. Proximity ligation assays were the only technique to demonstrate 52 
expression within glomeruli. This study demonstrated CaSR expression 53 
throughout the kidney with minimal discrepancy between species but with 54 
significant variation in the levels of expression between cell and tubule types.  55 
These findings clarify the intra-renal distribution of the CaSR and enable 56 
elucidation of the full physiological roles of the receptor within this organ. 57 
 58 
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Introduction 59 
The calcium sensing receptor (CaSR) is a G-protein coupled receptor with a key 60 
role in extracellular free ionized calcium (Ca2+o) homeostasis. The CaSR was 61 
first cloned and characterized in the parathyroid by Brown and coworkers in 62 
1993 (7) and subsequently identified in other organs involved in the control of 63 
Ca2+o, namely the kidney (37), GI tract (15) and bone (18). In addition, CaSR 64 
expression has been reported in tissues outside the Ca2+o homeostatic system 65 
such as the blood vessels (8), thyroid (16), nerve (38) and heart (42). In kidney 66 
the CaSR regulates calcium excretion by modulating the actions of parathyroid 67 
hormone (PTH) (26). However, the CaSR also regulates calcium excretion in a 68 
PTH-independent way, by controlling paracellular movement of Ca2+ in the thick 69 
ascending limb (TAL) through modulation of both the transepithelial potential 70 
difference and paracellular permeability (17, 40). Additional functions of the 71 
renal CaSR include renin release (23, 29), acidification (13, 33) and 72 
concentration of urine (39). The distribution of intra-renal CaSR is critical to 73 
elucidating the full functional role of the receptor. The initial characterization of 74 
CaSR expression in rat kidney assessed the distribution of CaSR mRNA by 75 
northern blot and in situ hybridization (ISH) (36, 37). Transcripts were detected 76 
predominantly in outer medulla and cortex, with stronger expression in the 77 
cortical medullary rays, indicating a predominant expression of CaSR in the TAL 78 
(37). More detailed analysis of transcripts in rat kidney using ISH and reverse 79 
transcription polymerase chain reaction (RT-PCR) in dissected rat nephron 80 
segments, demonstrated expression in glomeruli, proximal tubules (PT), 81 
medullary (mTAL) and cortical (cTAL) TAL, distal tubules (DT) and collecting 82 
ducts (CD) (36). Comparable protein distribution was subsequently described in 83 
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rat kidney using immunofluorescence; expression was observed in PT, mTAL, 84 
cTAL, macula densa cells, DT and type A intercalated cells in cortical CDs 85 
(CCDs). In addition, the authors observed different cellular polarity of the 86 
receptor in different cell types along the nephron (35). Over the last decade, 87 
more detailed studies have been undertaken to address the precise localisation 88 
of the CaSR within the glomerulus. Expression has been demonstrated in 89 
juxtaglomerular cells (23, 29), activation of which inhibits renin release via an 90 
indirect effect on enzymes (adenylyl cyclase 5, phosphodiesterase 1C) that are 91 
the targets of the classical renin stimuli (30). Furthermore, calcimimetics inhibit 92 
plasma renin activity in a PTH-independent fashion both in vitro and in vivo (1, 93 
20, 23). Consistent with CaSR expression in glomerular podocytes, 94 
calcimimetics ameliorate toxin-induced glomerulosclerosis via antiapoptotic and 95 
cytoskeleton-stabilizing effects (28). CaSR expression has also been 96 
demonstrated in mouse (20) and human (25) mesangial cells and has been 97 
shown to mediate Ca2+ influx and cell proliferation via the canonical transient 98 
receptor potential channels 3 and 6.  99 
Since the initial characterization of CaSR expression in the kidney, the majority 100 
of studies have supported expression of the CaSR in rat TAL, DT and CD (11, 101 
14, 39, 45). However these studies have failed to agree on the distribution of 102 
the CaSR within the CD and also whether expression is present in the PT and 103 
glomerulus. RT-PCR on dissected rat nephron segments led to discrepant 104 
results with some groups reporting CaSR mRNA expression in the PT (36), and 105 
in the glomeruli (11) while others failed to demonstrate CaSR expression in 106 
theses nephron segments (11, 45). CaSR protein expression is also 107 
controversial, with some authors reporting CaSR expression in the PT (notably 108 
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at the apical membrane) using immunofluorescence on sections of frozen rat 109 
(34) and mouse kidney (3) while recent studies using human, mouse and rat 110 
kidney tissue failed to observe CaSR expression throughout the kidney with the 111 
exception of the TAL (22). 112 
The main problems associated with these seemingly contradictory results is that 113 
the studies describing the expression of the CaSR have differed in whether they 114 
have investigated mRNA or protein expression, used different fixation and/or 115 
immunostaining methodologies and have utilized different species. It is 116 
plausible that discrepancies between studies have arisen as a consequence of 117 
a lack of sensitivity with certain methods or non-specific detection of the CaSR. 118 
This study aimed to utilize technical advances in detection methods to gain 119 
greater sensitivity and specificity in determining CaSR expression in rat, human 120 
and mouse kidney. Using a combination of a branched DNA ISH, 121 
immunohistochemistry (using antibodies raised against different epitopes of the 122 
CaSR) and a highly sensitive and specific chromogenic in situ proximity ligation 123 
assay (PLA) method we have demonstrated CaSR expression throughout the 124 
kidney. These observations will help to describe the full physiological role of the 125 
CaSR in the kidney.  126 
 127 
Methods 128 
Tissue Samples 129 
Animal kidney tissue was obtained from adult CD-1 mice or Han Wistar rats, 130 
supplied by Harlan (Hillcrest, Leicestershire, UK) or Charles River (Harlow, 131 
Essex, UK). Tissue from kidney-specific CaSR-deficient mice was obtained as 132 
previously described utilizing transgenic animals expressing Cre recombinase 133 
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under the Sine oculis homeobox homolog 2 promoter (Six2-Cre Casr floxed 134 
mice) (40). Animals were killed by schedule 1 methods under the UK Animals 135 
(Scientific Procedures) Act (1986). Adult normal human kidney cortex tissue 136 
used for immunohistochemistry was obtained from the AstraZeneca Global 137 
Tissue Bank, compliant with the UK Human Tissue Act (HTA) and AstraZeneca 138 
global policies. Adult human kidney tissue used for western blotting was 139 
obtained from human kidneys surgically resected at The University Hospital 140 
Wales due to renal cell carcinoma (RCC) (Research Ethics Committee approval 141 
reference number: 07/WSE04/53) in collaboration with the Wales Cancer Bank. 142 
Macroscopically normal kidney cortex tissue was taken from a region separate 143 
to the carcinoma.  144 
 145 
In situ hybridization  146 
Mouse, rat and human kidneys were fixed in 10% neutral-buffered formalin for 147 
24 to 48h and embedded in paraffin. 5 µm thick sections were cut and ISH was 148 
performed using QuantiGene ViewRNA ISH tissue assay (Affymetrix, Santa 149 
Clara, CA, USA) according to manufacturer’s instructions, with the following 150 
modifications: incubation times were 5 min for pretreatment, 20 min for protease 151 
digestion, 40 min for PreAmp Hybridization, and 30 min for Amp Hybridization 152 
and Label Probe (alkaline phosphatase conjugated probe) incubation. Rat and 153 
human specific CaSR probes were obtained from Affymetrix and used at a 154 
dilution of 1:40 in the probe diluents provided in the kit. For mouse tissue, a rat 155 
probe was used since preliminary experiments showed good species cross-156 
reactivity (rat and mouse CaSR sequences share 94% homology). Sections 157 
were mounted using Immu-mount (Thermo Scientific, Waltham, MA, USA). 158 
 8
Negative controls were performed using both a scrambled CaSR probe and an 159 
anti-sense probe complementary to the CaSR sense probe. 160 
 161 
Immunofluorescence 162 
The antibodies used in this study were screened by immunofluorescence 163 
patterns in HEK293 cells stably transfected with the human CaSR (CaSR-HEK), 164 
as described previously (24). Cells were fixed in 4% paraformaldehyde in 165 
phosphate-buffered saline (PBS), washed and incubated in PBS containing 50 166 
mM NH4Cl for 10 min. Blocking was performed using 1% bovine serum 167 
albumin/0.05% Triton-X 100 in PBS. Primary antibodies (Table 1: Abs 1-8) were 168 
incubated overnight at 4ºC at a dilution of 1:100 in blocking buffer. Alexa Fluor 169 
488 or Alexa Fluor 594 fluorescence-dye coupled secondary anti IgG antibodies 170 
(Life Technologies, Paisley, UK) were incubated at a dilution of 1:500 in 171 
blocking buffer to visualize primary antibody binding. Hoechst 34580 (Life 172 
Technologies) was used to stain the nuclei. 173 
 174 
Western Blotting 175 
Mouse, rat and human kidney samples and CaSR-HEK or untransfected 176 
HEK293 cells were homogenized in modified RIPA buffer (25 mM Tris HCl pH 177 
7.6, 150 mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate, 1% sodium 178 
deoxycholate, 1mM n-ethylmaleimide, 1 mM phenylmethanesulfonylfluoride) 179 
containing Halt protease and phosphatase inhibitors (Thermo Scientific). Cell 180 
lysis was carried out using a Polytron (Kinematica, Bohemia, NY, USA) 181 
homogenizer. Following lysis, homogenates were centrifuged at 10,000 x g for 5 182 
min to remove insoluble debris. Protein extracts were quantified using a BCA 183 
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protein assay (Thermo Scientific). 20 µg of each extract were subjected to 184 
electrophoresis on NuPage® 10% BisTris polyacrylamide gels (Life 185 
Technologies). Gels were transferred to nitrocellulose membranes and stained 186 
with Ponceau S to confirm even protein loading. Non-specific protein binding 187 
was prevented using 5% low-fat dried milk in Tris-buffered saline containing 188 
0.1% Tween (TBST) for 1h at room temperature. Primary antibodies (Table 1: 189 
N-term1, N-term2, C-term1 and full length) were added at a dilution of 1:2000 in 190 
5% milk/TBST overnight at 4ºC. A horseradish peroxidase (HRP) conjugated 191 
anti-mouse or anti-rabbit secondary antibody (Promega, Madison, WI, USA) 192 
was added at a dilution of 1:20,000 or 1:6,000, respectively, in 5% milk/TBST 193 
before detection of immunoreactivity with ECL prime using a ChemiDoc MP 194 
(Biorad, Hercules, CA, USA). 195 
 196 
Immunohistochemistry 197 
Mouse, rat and human kidneys were fixed in 10% neutral-buffered formalin for 198 
24 to 48h and embedded in paraffin. 4 µm thick sections were cut, de-waxed in 199 
xylene and rehydrated in ethanol. Antigen retrieval was performed in a 200 
Milestone RHS-2 microwave (Milestone, Sorisole, Italy) at 110°C for 2 min in 1 201 
mM ethylenediaminetetraacetic acid (EDTA) buffer, pH 8. Endogenous 202 
peroxidase activity was blocked with 3% aqueous hydrogen peroxide for 10min. 203 
Immunostaining was carried out using a Labvision autostainer (Labvision, 204 
Fremont, CA, USA). Nonspecific binding of the antibody was prevented by 205 
incubating slides with background blocker with casein (Menarini, Florence, Italy) 206 
for 20 min. Slides were incubated with primary antibodies (Table 1: N-term1, N-207 
term2, full length and C-term1) for 1h at room temperature. Primary antibodies 208 
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were detected with X-Cell Plus HRP (Menarini), Envision anti-mouse labeled 209 
polymer (DAKO, Glostrup, Denmark) or Ultravision Quanto Mouse on Mouse 210 
(Thermo Scientific), and peroxidase was visualized with diamino benzidine 211 
(Menarini). Double labeling was performed by incubating tissue sections with 212 
antibodies against aquaporin 2 (AQP2, 1:4000, Sigma, St Louis, MO, USA), 213 
Tamm Horsfall (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or the 214 
thiazide-sensitive NaCl cotransporter (NCC, 1:500, Millipore, Billerica, MA, 215 
USA) as nephron segment markers for 1h at room temperature. AQP2, Tamm 216 
Horsfall and NCC were detected by 30 min incubation with goat anti-rabbit 217 
antibody conjugated with alkaline phosphatase (Life Technologies), and 218 
visualized using Quanto Fast Red Permanent (Thermo Scientific). Sections 219 
were counterstained with haematoxylin before dehydration in ethanol, clearing 220 
in xylene, and mounting using Hystomount (TAAB Labs, Aldermaston, UK). 221 
Negative controls were performed using the appropriate isotype or no primary 222 
antibody controls.  223 
 224 
Proximity ligation assay 225 
Proximity ligation assays (PLA) were performed using the Duolink® assay with 226 
brightfield detection (Sigma) according to the manufacturer’s instructions. 227 
Briefly, 5 µm thick sections were cut and antigen-retrieval and peroxidase 228 
quenching were carried out as described for IHC. Sections were incubated with 229 
primary antibody pairs (N-term1/N-term2, N-term1/N-term6, full length/N-term6, 230 
C-term1/N-term2, C-term1/N-term6) for 1h at room temperature. Primary 231 
antibody pairs were detected by secondary antibodies conjugated with 232 
oligonucleotide probes (anti-Rabbit PLA probe Plus and anti-Mouse PLA probe 233 
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Minus), incubated for 1h at 37°C. Ligation of the probes was performed by 234 
adding oligonucleotides capable of hybridizing to the two probes and ligase 235 
enzyme for 30 min at 37°C. Amplification was carried out by adding nucleotides 236 
and polymerase enzyme and incubating for 2h at 37°C. Detection was 237 
performed by incubation with HRP-conjugated oligonucleotide probes for 1h at 238 
room temperature. Peroxidase was then visualized with diamino benzidine 239 
(Menarini). Sections were counterstained with haematoxylin before dehydration 240 
in ethanol, clearing in xylene, and mounting using Hystomount (TAAB Labs). 241 
Negative controls were performed using the appropriate isotype or no primary 242 
antibody controls. Additional controls were performed by incubating rat sections 243 
with C-term1 and ki67 (1:200, Novus, Littleton, CO, USA) or N-term6 and alpha 244 
smooth muscle actin (SMA, 1:3000, Sigma). 245 
 246 
Immunoprecipitation 247 
Rat kidney samples were prepared as described for western blotting. 248 
Immunoprecipitation was performed using µMACS Protein G MicroBeads and µ 249 
Columns (Miltenyi Biotec, Cologne, Germany) according to the manufacturer’s 250 
instructions. Immunoprecipitation was performed to pull-down CaSR (3 µg, 251 
Thermo Scientific), SMA (3 µg, Sigma) and IgG2a (3 µg, Isotype control, 252 
Abcam, Cambridge, UK). 20 µl of each immunoprecipitated sample, the lysate 253 
pre-clearing flowthrough (negative control) and rat kidney extract (positive 254 
control) were subjected to electrophoresis on NuPage® 4-12% BisTris 255 
polyacrylamide gels (Life Technologies). Western blotting was performed as 256 
described above for SMA (1:2000, Sigma). Controls for western blotting were 257 
performed by omission of primary antibody. 258 
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 260 
Results 261 
CaSR mRNA expression 262 
Using ISH, all species showed a high expression of CaSR mRNA in cortical 263 
medullary rays (Figure 1A-C) and in the outer medulla (Figure 1D-F), consistent 264 
with CaSR expression in the TAL. Lower levels of CaSR mRNA were also 265 
detected in the DCT and cortical and medullary CDs, identified by distribution 266 
and morphology (Figure 1A-F). There was no signal detected in the papilla of rat 267 
and mouse (this region was not present in the human kidney samples). There 268 
was also no signal detected in the proximal tubules. Negative controls using 269 
either an anti-sense probe or a scrambled probe did not detect any positive 270 
signal (Figure 1G-I). 271 
 272 
CaSR protein expression 273 
Selection of antibodies  274 
To determine whether the discrepancy in expression patterns obtained in 275 
previously published studies could be ascribed to the use of different CaSR 276 
antibodies, nine antibodies raised against different regions of the CaSR protein 277 
were investigated in this study (Table 1). All antibodies, except N-term6, were 278 
initially screened using immunofluorescence on CaSR-HEK cells. For all 279 
antibodies, except C-term2, immunofluorescence was detected predominantly 280 
at the plasma membrane and in the cytoplasm of the cells (Figure 2). C-term2 281 
showed strong nuclear immunoreactivity, which was considered to be non-282 
specific, particularly as this has not been reported previously, and therefore was 283 
excluded from further experiments. 284 
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Western Blotting 285 
From the initial immunofluorescence screening process, four antibodies were 286 
selected to carry out further studies, based on their recognition of different 287 
CaSR epitopes. Antibodies N-term1, N-term3, N-term4, N-term5 all recognize 288 
the ADD amino acid sequence within the N-terminal of the CaSR and showed 289 
comparable immunofluorescence patterns, therefore only one was selected for 290 
further investigation. Out of these, N-term1 was chosen since it has been used 291 
most extensively in published studies. N-term2 was selected because it was the 292 
only antibody raised against a different epitope within the N-terminal, according 293 
to the manufacturer’s information; full length and C-term1 antibodies were 294 
selected as they were the only available antibodies raised against the full length 295 
protein and against the CaSR C-terminal domain, respectively.  296 
In order to further confirm the specificity of these antibodies, western blot 297 
profiles were analyzed using mouse, rat and human kidney and CaSR-HEK cell 298 
extracts (Figure 3). Immunostaining carried out using N-term1 and N-term2 299 
exhibited CaSR-like immunoreactivity in all 3 species. Conversely, no specific 300 
CaSR immunoreactivity was observed in untransfected HEK293 cells 301 
immunostained with N-term1 and N-term2. The full length antibody only 302 
recognized the CaSR in human tissue and CaSR-HEK cells, consistent with this 303 
antibody being raised against a human antigen. C-term1 only cross-reacted with 304 
the mouse and rat tissue, consistent with this antibody being raised against a 305 
mouse antigen. Unfortunately the antibodies that had been raised against the 306 
full-length protein did not cross-react with mouse or rat kidney tissue, while the 307 
antibody against the C-terminal region of the CaSR protein did not recognize 308 
human kidney tissue. Immunoreactivity of the expected size, that is 140-160 309 
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kDa for the glycosylated monomer and/or 260-300 kDa for the mature, fully 310 
glycosylated CaSR dimer (43), were observed with all the antibodies. The 311 
western blotting profiles revealed some differences between antibodies. Using 312 
N-term1, strong immunoreactivity was detected for all the samples; in mouse 313 
and rat kidney, immunoreactivity corresponding to the CaSR monomer was 314 
detected more strongly than the dimer whereas in human and CaSR-HEK 315 
samples the signal distribution was more homogeneous. N-term2 antibody 316 
detected preferentially the dimeric form of the CaSR compared to the monomer 317 
in all three species. Full length detected very weak CaSR immunoreactivity in 318 
human kidney lysate but a stronger signal was obtained in CaSR-HEK lysate. 319 
This antibody appeared to detect the monomer and dimer equally well. C-term1 320 
preferentially detected the monomeric form of the CaSR compared with the 321 
dimer in both mouse and rat, but it did not cross react with human or CaSR-322 
HEK samples). Thus, further immunohistochemistry studies for each species 323 
utilized the following antibodies: N-term1, N-term2 and C-term1 for mouse and 324 
rat kidney and N-term1, N-term2 and whole for human kidney. 325 
 326 
CaSR protein expression 327 
Having selected suitable antibodies, the CaSR intra-renal distribution was 328 
investigated in sections of kidney tissue. Generally, the strongest 329 
immunoreactivity was detected in the outer medulla and medullary rays and 330 
weak immunoreactivity was detected in the cortex for all the species (Figures 4-331 
6A-F). CaSR immunoreactivity in the different nephron segments was assessed 332 
by analysing cellular morphology and co-staining using the CaSR antibodies in 333 
combination with established segment-specific markers (Figure 4G-R (mouse), 334 
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Figure 5G-R (rat), and Figure 6G-R (human)). In general, CaSR 335 
immunoreactivity was found all along the nephron, with a comparable 336 
expression pattern across the different species. Specifically, all antibodies 337 
detected CaSR immunoreactivity at the basolateral membrane and cytoplasm of 338 
the TAL, identified by colocalization with Tamm Horsfall protein (Figures 4-339 
6H,L,P). Consistent with the mRNA distribution by ISH, IHC showed that CaSR 340 
immunoreactivity was strongest in the TAL. In addition, CaSR immunoreactivity 341 
was consistently detected by all antibodies in the DCT, identified by 342 
colocalisation with antibodies directed against NCC (Figures 4-6I,M,Q). In this 343 
segment, immunoreactivity was detected apically, basolaterally and within the 344 
cytoplasm. CaSR was also present in the connecting tubule (CNT), identified by 345 
a combination of morphology and NCC-negative, AQP2-positive cells. In the 346 
CDs, identified by a combination of co-localization with AQP2 and morphology 347 
(Figures 4-6J,N,R), CaSR expression was heterogeneous. In mouse and rat, 348 
CaSR immunoreactivity was found at the basolateral membrane of some 349 
cortical CD cells and in the apical membrane and cytoplasm of other cortical CD 350 
cells. In CDs in the medulla and papilla, CaSR expression was only observed 351 
with N-term2, which showed apical and basolateral immunoreactivity. In human 352 
tissue, CaSR immunoreactivity was detected in the cytoplasm and apical and 353 
basolateral membranes of most cortical CD cells. Stronger immunoreactivity 354 
was detected in a population of CD cells when antibodies N-term1 or N-term2 355 
were used. With N-term2, CaSR immunoreactivity was observed within all cells 356 
in the CCDs and therefore all Aqp2 positive cells were also positive for the 357 
CaSR. In the inner and outer medullary CDs (MCDs) and also for all the 358 
remaining antibodies some cells were CaSR+/Aqp2+, some CaSR+/Aqp2-, 359 
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some CaSR-/Aqp2+ and some CaSR-/Aqp2-. CaSR immunoreactivity was very 360 
weak in the PT (identified by the presence of brush border) with N-term1, full 361 
length and C-term1 (Figures 4-6I,Q). In this segment the intensity of 362 
immunostaining signal varied between repeat experiments and in some cases 363 
was difficult to distinguish from background levels obtained with isotype 364 
controls. However, N-term2 (Figures 4-6M) consistently detected relatively 365 
strong immunoreactivity in the cytoplasm and apical membrane of PT cells, 366 
which generally increased from the S1 segment down to the S3 segment of the 367 
PT. CaSR immunoreactivity was absent or very weak (indistinguishable from 368 
background) in the glomeruli and JGA. No specific immunoreactivity was 369 
detected in kidney sections from mice deficient in the renal CaSR 370 
immunostained with N-term1 or C-term1, or in the corresponding isotype 371 
controls (Figure 7).  However, N-term2 displayed positive signal throughout the 372 
kidney in the KO mice.  Some signal was observed in the isotype control for this 373 
antibody however the signal with N-term2 appeared to be of greater intensity 374 
(data not shown).  375 
 376 
Proximity ligation assay 377 
Antibody pairs were initially selected for PLA on their ability to recognise 378 
different regions of the CaSR protein, to maximise the chance of signal being 379 
observed from the same protein molecule. PLA on mouse and rat kidney using 380 
the C-term1/N-term6 antibody pair or in human kidney using the full length/N-381 
term6 antibody pair indicated that, similar to the ISH and IHC results, CaSR 382 
expression was greatest in the outer medulla and medullary rays and weaker in 383 
the cortex (Figure 8). This distribution clearly demonstrates stronger expression 384 
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of the CaSR in the TAL and weaker expression in the DT and CD. Consistent 385 
with the ISH and conventional IHC, both positive and negative cells were 386 
observed within the CD (Figure 9). Importantly, PLA signal was detected in the 387 
PT, with S3 showing higher expression than S1, consistent with conventional 388 
IHC using N-term2. In the glomeruli, a positive signal was detected but at a low 389 
level, comparable to the proximal tubule expression. The low level of signal 390 
combined with the cytoplasmic distribution precluded any determination of 391 
positive cell types within the glomerulus. Negative controls showed only the 392 
occasional dot of false-positive signal but these were generally associated with 393 
areas of the section containing no tissue (i.e. lumen of tubules or blood 394 
vessels). PLA in rat kidney using other antibody pairs including N-term1/N-395 
term2, N-term1/N-term6, N-term2/C-term1 showed similar results to the C-396 
term1/N-term6 antibody pair (Figure 10). Incubation of rat kidney sections with a 397 
C-term1/anti-ki67 antibody pair (used as an antibody to an unrelated protein) 398 
also displayed only the occasional dot of positive signal (Figure 11A,B). A 399 
further control was conducted using the N-term6 and an anti-SMA antibody pair 400 
on rat kidney sections. The CaSR and SMA may interact at a molecular level 401 
since both proteins have been demonstrated to interact with filamin (2, 21) and 402 
so should result in a positive PLA signal. However, in the kidney, SMA is only 403 
expressed in the blood vessels and not in epithelial cells. Accordingly, PLA 404 
signal was not observed within cells of the nephron but only in blood vessels 405 
(Figure 11C). The specificity of the signal was confirmed by analysing the 406 
interaction between the CaSR and SMA with a co-immunoprecipitation assay: 407 
SMA expression was observed by western blotting using rat kidney extracts 408 
immunoprecipitated with the N-term1 antibody, suggesting that there is an 409 
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interaction of the CaSR and SMA in vascular smooth muscle cells (Figure 11D). 410 
The results from the ISH, IHC and PLA experiments are summarized in Table 2. 411 
 412 
Discussion 413 
Recent accumulating evidence supports a direct role for the CaSR in the 414 
kidney, independent of its indirect, PTH-mediated actions. Yet, its intrarenal 415 
distribution is still controversial. Pharmacological CaSR modulators are either in 416 
use in the clinic (calcimimetics) (6) or are currently being developed for the 417 
treatment of genetic hypocalcemia with hypercalciuria (autosomal dominant 418 
hypocalcemia, calcilytics) (27). Therefore, the aim of the current study was to 419 
determine, conclusively and unequivocally, the intra-renal distribution of the 420 
CaSR using the most sensitive and specific detection methods available for 421 
examining large numbers of each renal cell type across different species. This 422 
knowledge is essential to fully elucidate the role of the CaSR in the kidney and 423 
key to discriminating between CaSR-dependent and CaSR-independent roles of 424 
physiological and pharmacological CaSR modulators in the kidney. Because 425 
some of the discrepancies were previously ascribed to species differences, we 426 
assessed both CaSR mRNA and protein localisation in mouse, rat and human 427 
kidneys. For protein localisation, we tested a wide variety of commercially and 428 
non-commercially available antibodies, raised against different regions of the 429 
CaSR protein. The initial screening of antibodies using immunofluorescence 430 
indicated that seven out of the eight investigated antibodies specifically 431 
detected the CaSR in positively transfected cells, but not in sham-transfected 432 
cells. This result suggests that false positive protein detection is unlikely to be a 433 
major cause of discrepancies between studies. One antibody, C-term2, did fail 434 
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this initial screen although this could be due to an inability of this antibody to 435 
detect the correct antigen following paraformaldehyde fixation. 436 
Consistent with previous reports, western blotting showed the expected 437 
heterogeneity of CaSR species present in the kidney given by the combination 438 
of the nude protein, the high mannose and fully mature monomeric and dimeric 439 
CaSR (4, 5, 43). Interestingly, the battery of antibodies tested showed different 440 
profiles for the detection of the different molecular species. Despite the different 441 
western blotting profiles, there was generally a consistent pattern of protein 442 
expression by immunohistochemistry, regardless of the antibody used. N-term2 443 
displayed a slightly different profile by immunohistochemistry compared to N-444 
term1 and C-term1, notably a more intense expression of the CaSR in proximal 445 
tubules. By western blotting this antibody was the only antibody to 446 
predominantly detect dimeric forms of the CaSR. Since the dimerization is an 447 
essential step in the maturation of the CaSR(31), it is possible that N-term2 has 448 
a greater sensitivity to detect more mature forms of this receptor than the 449 
remaining antibodies. Alternatively, this antibody may display some non-specific 450 
binding in FFPE tissue in addition to CaSR binding. The lack of specificity of this 451 
antibody in FFPE tissue is supported by the positive signal obtained in the 452 
CaSR deficient kidney tissue.  In contrast, the specificity of the signal detected 453 
by the N-term1 and N-term 2 antibodies was confirmed in mice with selective 454 
CaSR ablation from the kidney.    455 
 456 
Loop of Henle and distal tubule 457 
The highest CaSR mRNA and protein expression were observed basolaterally 458 
in the TAL, the only segment unanimously recognized to express the CaSR (3, 459 
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10, 22, 34, 40, 45). Functional studies have shown that the CaSR inhibits PTH-460 
induced transcellular divalent cation reabsorption in this nephron segment (26). 461 
Also, in this nephron segment CaSR activation directly inhibits paracellular 462 
divalent cation reabsorption through PTH-independent processes (22, 40). 463 
These processes are associated with the modulation of transepithelial potential 464 
difference through the inhibition of Na-K-Cl cotransporter 2 (NKCC2) activity 465 
(40) and with the epigenetic regulation of micro RNA controlling claudin 14 466 
expression (17, 40). Expression of both CaSR mRNA and protein was also 467 
observed in the DCT, and functional expression of CaSR in DCT has been 468 
previously linked to regulation of Ca reabsorption from the pro-urine via TRPV5 469 
(41) and to regulation of Kir4.1 (19). 470 
Collecting ducts 471 
Within the collecting ducts, all techniques demonstrated greatest CaSR 472 
expression in CCD compared with outer and inner MCDs. IHC with N-term2 and 473 
PLA demonstrated a lower expression of CaSR in MCDs that was not observed 474 
with other techniques. With the exception of IHC with N-term2, all methods 475 
(including PLA) revealed that only a proportion of CCDs were positive for CaSR 476 
expression (approximately 30%).  Whilst it cannot be ruled out that N-term2 477 
shows greater sensitivity than all the other techniques, it is more likely that this 478 
antibody is either recognising non-specific signal in addition to the CaSR in 479 
FFPE tissue, or it is the only method to detect a specific form of the receptor. 480 
Given the significantly greater signal for the dimer observed by western blotting 481 
with this antibody (compared to the others), the latter explanation is a 482 
possibility. CaSR positive CD cells could not be attributed to being either 483 
principal or intercalated cells since populations of CaSR+/AQP2+, 484 
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CaSR+/Aqp2-, CaSR-/Aqp2+ and CaSR-/Aqp2- were clearly observed. In 485 
agreement with the original description of CaSR localisation in CCDs (34), 486 
heterogeneous expression within the cytoplasm, apical and/or basolateral 487 
membranes was observed in the current study. Characterisation of the cell 488 
types in the study by Riccardi et al demonstrated CaSR expression in some, but 489 
not all, type A intercalated cells (34).  Functionally this is supported by studies in 490 
TRPV5−/− mice, where the CaSR is activated by increased urinary Ca2+ levels, 491 
which triggers urinary acidification by increasing the H+-ATPase activity (33). 492 
Principal cell expression is also suggested by studies demonstrating that 493 
activation of an apical CaSR expression in CDs is specifically involved in 494 
reduction of AVP-elicited osmotic water permeability via reduction of Aqp2 (9, 495 
32, 39). Recently, pH-sensitive CaSR expression was described as being 496 
restricted to the basolateral membrane of type B intercalated cells (46), 497 
although the images presented appeared to show weaker staining in N-term2 498 
and anion exchanger 1 positive cells. Our data support the presence of the 499 
CaSR in both principal and intercalated cells, with significant heterogeneity in 500 
expression levels and also polarity. Further work is needed to elucidate the 501 
reasons behind the restricted expression of the CaSR to subpopulations of 502 
these different cell types. 503 
Proximal tubule 504 
The proximal tubule is the nephron segment where greatest discrepancies in 505 
CaSR expression have been reported between studies. Our data with IHC and 506 
ISH was inconclusive since only one antibody, N-term2, convincingly showed 507 
proximal tubule expression. Since this antibody also showed signal in the CaSR 508 
deficient mice, this staining was likely to be non-specific.  The level of staining 509 
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with the other antibodies and also with ISH varied slightly between repeat 510 
experiments and was difficult to distinguish above possible background staining. 511 
However, using PLA we were specifically able to detect a low level of CaSR 512 
expression in the proximal tubule. This method confers greater specificity than 513 
conventional IHC since specific detection of the same molecule by a pair of 514 
antibodies is necessary to produce a positive signal. In addition the method 515 
includes an amplification step, further increasing the sensitivity over 516 
conventional methods. This finding supports functional studies demonstrating 517 
that, in mice, activation of the CaSR by increased luminal gadolinium blocks the 518 
inhibitory effect of PTH in phosphate absorption in the proximal tubule (3) and 519 
also that in both rats and mice, activation of the CaSR by increased luminal 520 
calcium concentration enhances fluid reabsorption in the proximal tubule (10). 521 
Finally, a recent study has demonstrated expression of a functional CaSR at the 522 
apical membrane of conditionally immortalized proximal tubular epithelial cells 523 
obtained from healthy urine (12). 524 
Glomerulus 525 
The majority of studies addressing CaSR expression in the kidney have failed to 526 
observe localisation within the glomerulus. In the current study, PLA was also 527 
the only technique to convincingly demonstrate CaSR expression within 528 
glomeruli. Functional effects of the CaSR have been described in both 529 
podocytes (28) and in cultured mesangial cells (20, 25). Interestingly our results 530 
showed considerable variation in CaSR expression within glomeruli from the 531 
same animal, even between adjacent glomeruli. The reason for this is not 532 
currently understood but could reflect differences in functional activity of 533 
individual glomeruli at a given time. 534 
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In conclusion, this study has demonstrated CaSR expression throughout the 535 
nephron and in glomeruli, although the level of expression varied considerably 536 
between different cell types. A summary of the distribution and roles of the 537 
CaSR in the kidney is shown in Figure 12.  In contrast, there was little variation 538 
in the expression pattern between mouse, rat and human, suggesting 539 
conserved functions of the receptor between these species.  The highest CaSR 540 
expression was detected in the TAL, where this receptor regulates Ca2+ 541 
reabsorption. Besides, the CaSR was detected in different cell types from other 542 
nephron segments with significantly lower expression compared with the 543 
abundantly expressing cells of the TAL. These data corroborate previous 544 
functional studies showing CaSR expression in cell types where functional 545 
effects have been demonstrated specifically in the PT, DCT and CD. 546 
Furthermore, this information will prove valuable for studies aimed at testing the 547 
ability of calcimimetics in transplant patients (44) and of calcilytics for the 548 
treatment of hypercalciuria and nephrocalcinosis (27).  549 
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Figure Legends 555 
Table 1. Details of antibodies used in the study.  556 
*N-term1 is a monoclonal antibody produced using the 5C10, ADD clone and 557 
commercialized by different companies including Abcam, Thermo-Scientific, 558 
Novus Bio, Genetex (Irvine, CA, USA) and Acris (Herford, Germany). † 559 
Anaspec, Fremont, USA. ‡ LS Bio, Seattle, USA.  560 
 561 
Table 2. Summary of the localization of the CaSR observed by ISH, IHC 562 
and PLA. 563 
 564 
 565 
Figure 1. Localization of CaSR mRNA in mouse, rat and human kidney. 566 
Photomicrographs of in situ hybridization using probes directed against CaSR in 567 
cortical sections of mouse (A), rat (B) and human (C) kidney and in medullary 568 
sections of mouse (D) and rat (E) and human (E) kidney. CaSR signal (in red) 569 
corresponds to fast red staining and nuclei are counterstained with 570 
haematoxylin (blue). Photomicrographs of negative controls for the in situ 571 
hybridization in mouse (G), rat (H) and human (I) cortical sections. Negative 572 
controls were performed by incubation with anti-sense probes (rat) or omission 573 
of CaSR probe (mouse and human). Scale bar = 50 µm. Arrows indicate 574 
stronger staining, consistent with TAL expression; arrowheads indicate weaker 575 
expression, consistent with DT and CD. Pictures are representative of three 576 
(mouse and rat) or two (human) independent experiments. 577 
Figure 2. CaSR immunolocalization in HEK293 cells stably expressing the 578 
human CaSR. Immunofluorescence using eight different anti-CaSR antibodies, 579 
N-term1 (Abcam), N-term2 (Anaspec), N-term3 (W. Chang), N-term4 (W. 580 
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Chang), N-term5 (W. Chang), C-term1 (W. Chang), C-term2 (Lifespan), full 581 
length (Novus). Scale bar = 30 µm. 582 
 583 
Figure 3. Western blotting profile for the different CaSR antibodies used in 584 
this study. Western blotting using N-term1 (Thermo), N-term2 (Anaspec), full 585 
length  (Novus) and C-term1 (W. Chang) antibodies in mouse (Ms), rat (Rt) and 586 
human (Hu) kidney and CaSR-HEK (Hk) extracts (A). CaSR monomers and 587 
dimers are detected at 140-160 kDa and 260-300 kDa, respectively. Western 588 
blotting negative controls performed by omitting the primary antibodies (B). 589 
Western blotting using N-term1 and N-term2 antibodies in CaSR-HEK (Hk) and 590 
in untransfected HEK (Hk-Ø) cell extracts (C). 591 
 592 
Figure 4. CaSR immunolocalization in mouse kidney sections. 593 
Photomicrographs of mouse cortical kidney sections immunostained with the 594 
CaSR antibodies N-term1 (Thermo; A), N-term2 (Anaspec, B) and C-term1 (W. 595 
Chang, C). Photomicrographs of mouse medullary kidney sections 596 
immunostained with the CaSR antibodies N-term1 (D), N-term2 (E) and C-597 
term1 (F). Positive CaSR signal corresponds to immunoperoxidase staining 598 
(brown) and nuclei are counterstained with haematoxylin (blue). Arrows indicate 599 
stronger signal consistent with TAL and arrowheads indicate weaker signal 600 
consistent with DCT and CD. Photomicrographs showing CaSR 601 
immunoreactivity in the PT, identified by the presence of brush border in kidney 602 
sections immunostained with N-term1 (G), N-term2 (K) and C-term1 (O). 603 
Asterisk indicates the PT. Photomicrographs showing CaSR immunoreactivity in 604 
the TAL, identified by dual staining with Tamm Horsfall protein in kidney 605 
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sections immunostained with N-term1 (H), N-term2 (L) and C-term1 (P). 606 
Photomicrographs showing CaSR immunoreactivity in the DCT, identified by 607 
dual staining with the thiazide-sensitive Na-Cl cotransporter (NCC) in kidney 608 
sections immunostained with N-term1 (I), N-term2 (M) and C-term1 (Q). 609 
Photomicrographs showing CaSR immunoreactivity in the CD, identified by dual 610 
staining with Aquaporin-2 (AQP2) in kidney sections immunostained with N-611 
term1 (J), N-term2 (N) and C-term1 (R). Nephron segment marker signal 612 
corresponds to (red) fast red staining. Photomicrographs for the negative 613 
controls for N-term1 (S), N-term2 (T) and C-term1 (U), performed by omitting 614 
the primary antibody. Scale bar = 100 µm for pictures A-F and S-U and 50 µm 615 
for pictures G-R. 616 
 617 
Figure 5. CaSR immunolocalization in rat kidney sections. 618 
Photomicrographs of rat cortical kidney sections immunostained with the CaSR 619 
antibodies N-term1 (Thermo; A), N-term2 (Anaspec, B) and C-term1 (W. 620 
Chang, C). Photomicrographs of rat medullary kidney sections immunostained 621 
with the CaSR antibodies N-term1 (D), N-term2 (E) and C-term1 (F). Positive 622 
CaSR signal corresponds to immunoperoxidase staining (brown) and nuclei are 623 
counterstained with haematoxylin (blue). Arrows indicate stronger signal 624 
consistent with TAL and arrowheads indicate weaker signal consistent with DCT 625 
and CD. Photomicrographs showing CaSR immunoreactivity in the PT, 626 
identified by the presence of brush border in kidney sections immunostained 627 
with N-term1 (G), N-term2 (K) and C-term1 (O). Asterisk indicates the PT. 628 
Photomicrographs showing CaSR immunoreactivity in the TAL, identified by 629 
dual staining with Tamm Horsfall protein in kidney sections immunostained with 630 
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N-term1 (H), N-term2 (L) and C-term1 (P). Photomicrographs showing CaSR 631 
immunoreactivity in the DCT, identified by dual staining with the thiazide-632 
sensitive Na-Cl cotransporter (NCC) in kidney sections immunostained with N-633 
term1 (I), N-term2 (M) and C-term1 (Q). Photomicrographs showing CaSR 634 
immunoreactivity in the CD, identified by dual staining with Aquaporin-2 (AQP2) 635 
in kidney sections immunostained with N-term1 (J), N-term2 (N) and C-term1 636 
(R). Nephron segment marker signal corresponds to (red) fast red staining. 637 
Photomicrographs for the negative controls for N-term1 (S), N-term2 (T) and C-638 
term1 (U), performed by incubation with the corresponding isotype controls. 639 
Scale bar = 100 µm for pictures A-F and S-U and 50 µm for pictures G-R. 640 
Figure 6. CaSR immunolocalization in human kidney sections.  641 
Photomicrographs of human cortical kidney sections immunostained with the 642 
CaSR antibodies N-term1 (Thermo; A), N-term2 (Anaspec, B) and Full length 643 
(Novus, C). Photomicrographs of human medullary kidney sections 644 
immunostained with the CaSR antibodies N-term1 (D), N-term2 (E) and Full 645 
length (F). Positive CaSR signal corresponds to immunoperoxidase staining 646 
(brown) and nuclei are counterstained with haematoxylin (blue). Arrows indicate 647 
stronger signal consistent with TAL and arrowheads indicate weaker signal 648 
consistent with DCT and CD. Photomicrographs showing CaSR 649 
immunoreactivity in the PT, identified by the presence of brush border in kidney 650 
sections immunostained with N-term1 (G), N-term2 (K) and Full length (O). 651 
Asterisk indicates the PT. Photomicrographs showing CaSR immunoreactivity in 652 
the TAL, identified by dual staining with Tamm Horsfall protein in kidney 653 
sections immunostained with N-term1 (H), N-term2 (L) and Full length (P). 654 
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Photomicrographs showing CaSR immunoreactivity in the DCT, identified by 655 
dual staining with the thiazide-sensitive Na-Cl cotransporter (NCC) in kidney 656 
sections immunostained with N-term1 (I), N-term2 (M) and Full length (Q). 657 
Photomicrographs showing CaSR immunoreactivity in the CD, identified by dual 658 
staining with Aquaporin-2 (AQP2) in kidney sections immunostained with N-659 
term1 (J), N-term2 (N) and Full length (R). Nephron segment marker signal 660 
corresponds to (red) fast red staining. Photomicrographs for the negative 661 
controls for N-term1 (S), N-term2 (T) and Full length (U), performed by omitting 662 
the primary antibody. Scale bar = 100 µm for pictures A-F and S-U and 50 µm 663 
for pictures G-R. 664 
 665 
Figure 7. CaSR immunostaining in mice lacking the renal CaSR. 666 
Photomicrographs of cortical kidney sections from WT mice immunostained with 667 
the CaSR antibodies N-term1 (A) and C-term1 (B) or with the corresponding 668 
isotype control (C). Photomicrographs of cortical kidney sections from mice 669 
lacking the renal CaSR (D-F) immunostained with the CaSR antibodies N-term1 670 
(D) and C-term1 (E) or with the corresponding isotype control (F). Positive 671 
signal corresponds to immunoperoxidase staining (brown) and nuclei are 672 
counterstained with haematoxylin (blue). Scale bar = 100µm. 673 
 674 
Figure 8. CaSR detection by proximity ligation assay in mouse, rat and 675 
human kidney. Photomicrographs of CaSR immunolocalization by proximity 676 
ligation assay in mouse (A), rat (C) and human (E) cortical kidney sections. 677 
Immunoperoxidase staining (brown dots) indicates the proximity between the 678 
epitopes detected by the C-term1/N-term6 antibody pair in mouse and rat 679 
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sections and by the full length/N-term6 antibody pair in human sections. 680 
Photomicrographs of the negative controls performed by incubation with isotype 681 
control or omission of primary antibody (mouse, B; rat, D; human, F). Arrow 682 
indicates TAL and asterisk indicates PT. Scale bar = 50µm. 683 
Figure 9. CaSR expression in rat kidney CD. Photomicrographs of CaSR 684 
mRNA expression in CCD detected by ISH (A). Positive signal (as detected by 685 
ISH) corresponds to fast red staining. Photomicrographs of CaSR protein 686 
expression in CCD detected by IHC with N-term1 (Thermo, B), N-term2 687 
(Anaspec, C), C-term1 (W. Chang, D) or PLA with C-term1/N-term6 (Alomone, 688 
E). Photomicrographs of CaSR protein expression in outer MCD, detected by 689 
PLA with C-term1/N-term6 (F). Positive signal corresponds to 690 
immunoperoxidase staining (brown) and nuclei are counterstained with 691 
haematoxylin (blue) in IHC and PLA images. Scale bar = 50 µm. 692 
 693 
Figure 10. CaSR detection by proximity ligation assay in rat kidney. 694 
Photomicrographs of proximity ligation assay using the CaSR antibody pair N-695 
term1/N-term6 in outer (A) and inner (B) cortical kidney sections. 696 
Photomicrographs of proximity ligation assay using the CaSR antibody pair N-697 
term1/N-term2 in outer (C) and inner (D) cortical kidney sections. 698 
Photomicrographs of proximity ligation assay using the CaSR antibody pair N-699 
term2/C-term1 in outer (E) and inner (F) cortical kidney sections, (E). Positive 700 
staining corresponds to immunoperoxidase staining (brown dots). Asterisks 701 
indicate proximal tubules. Scale bar = 50 µm. 702 
 703 
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Figure 11. Controls for CaSR detection by proximity ligation assay in rat 704 
kidney. Photomicrograph of the negative control for the proximity ligation assay 705 
using the C-term1/anti-ki67 antibody pair in an outer cortical kidney section (A). 706 
Photomicrograph of the negative control for the proximity ligation assay using 707 
the N-term6/anti-SMA antibody pair in an outer cortical kidney section (B). 708 
Photomicrograph of the proximity ligation assay signal observed using the N-709 
term6/anti-SMA antibody pair in a renal blood vessel (C). Positive staining 710 
corresponds to immunoperoxidase staining (brown dots). Scale bar = 50 µm for 711 
the outer cortex pictures and 100 µm for the magnified blood vessel. The 712 
interaction between SMA and CaSR in blood vessels was confirmed by co-713 
immunoprecipitation: proteins from rat kidney extracts were immunoprecipitated 714 
with N-term1, anti-SMA or an IgG control. The immunoprecipitated proteins, 715 
together with the buffer used to pre-clear the assay columns (pc) and total 716 
protein extracts (Rt) were analysed by western blotting with an anti-SMA 717 
antibody (D). Control for the western blotting was performed by omitting the 718 
primary antibody (E). SMA MW = 42 kDa. 719 
 720 
Figure 12. Distribution and roles of the CaSR in the kidney. Diagrams 721 
representing the intra-renal distribution (left) and polarity (right) of the CaSR 722 
observed in this study, which is comparable in mouse, rat and human kidney. 723 
The strongest CaSR expression was observed in the TAL (dark grey) using in 724 
situ hybridization, immunohistochemistry and proximity ligation assay, however 725 
the CaSR was also consistently detected in the DCT/CNT and CD by these 726 
three techniques (medium grey). Additionally, weak CaSR expression was 727 
detected in the glomerulus and PT using a proximity ligation assay (light gray). 728 
The diagrams also summarize functional roles previously reported for the CaSR 729 
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in the different nephron segments. PT, proximal tubule; tDL, thin descending 730 
limb; tAL, thin ascending limb; TAL, thick ascending limb; DCT, distal 731 
convoluted tubule; CNT connecting tubule; CD, collecting duct; TRPC 3/6, 732 
transient receptor potential cation channel 3/6; PTH1R, parathyroid hormone 1 733 
receptor; NHE3, sodium–hydrogen exchanger 3; NKCC2, Na-K-Cl cotransporter 734 
2; ROMK, renal outer medullary K+ channel; TRPV5, transient receptor 735 
potential vanilloid 5; PMCA, plasma membrane Ca2+-ATPase; Kir 4.1, inward 736 
rectifying potassium channel 4.1; AQP2, aquaporin 2. 737 
 738 
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Antibody Manufacturer Reactivity Epitope Host Clone IHC Dilution Species Region
N-term1 Abcam (ab19347) / Thermo (MA1-934) * 
Mouse, 
Rat, 
Human 
Human 
N-term (ADD)
N’-ADDDYGRPGIEKFREEAEERDI-C’ Mouse Mono 1:500 
N-term2 Anaspec †  (53286) 
Mouse, 
Rat, 
Human 
Rat N-term Rabbit Poly 1:500 
N-term3 W. Chang (custom made) 
Mouse, 
Rat, 
Human 
Human N-term (ADD) N’-DYGRPGIEKFREEAEE-C’ Mouse Mono
Not 
tested 
N-term4 W. Chang (custom made) 
Mouse, 
Rat, 
Human 
Human N-term (ADD) N’-DYGRPGIEKFREEAEE-C’ Mouse Mono
Not 
tested 
N-term5 W. Chang (custom made) 
Mouse, 
Rat, 
Human 
Human N-term (ADD) N’-ADDDYGRPGIEKFREEAEERDI-C’ Rabbit Poly 
Not 
tested 
N-term-6 Alomone (ACR-004) 
Mouse, 
Rat, 
Human 
Human N-term (ADD) Rabbit Poly 1:500 
C-term1 W. Chang (custom made) 
Mouse, 
Rat Mouse 
C-term
N’-NSEDRFPQPERQKQ-C’ Mouse Mono 1:150 
C-term2 LS Bio‡ (LS-C117834) 
Mouse, 
Rat, 
Human 
Human C-term aa854-903 Rabbit Poly 
Not 
tested 
Full length Novus Bio (H00000846-B01P) Human Human Full length Mouse Poly 1:75 
 
  Glomerulus PT TAL DCT CNT CCD MCD 
ISH - - ++++ ++ + ++ + 
IHC 
N-term1 - +/- ++++ ++ + ++ - 
N-term2 - ++ ++++ ++ ++ ++ ++ 
Full length - +/- ++++ ++ + ++ - 
C-term1 - +/- ++++ ++ + ++ - 
 
PLA 
C-term1/N-term6 + + ++++ ++ + ++ + 
Full length/N-
term6 + + ++++ ++ + ++ + 
 












